NACDS resumes ad campaign promoting role of pharmacy
ALEXANDRIA, Va. — The National Association of Chain Drug Stores has resumed its paid advertising campaign promoting the role of pharmacy in the healthcare delivery system.
Since 2007, the NACDS has emphasized its theme of "Pharmacies, the face of neighborhood health care,” and will continue emphasizing the value of pharmacy with the message this week.
“It was not too long ago that one could feel the frustration of the pharmacy community,” wrote NACDS president and CEO Steve Anderson in an NACDS member e-newsletter. “There was a sense that those who understand the power of pharmacy services were talking among themselves but that the message was not reaching public policy and political constituencies. In other words, there was too much ‘preaching to the choir.’ That is changing dramatically.”
Anderson noted that the timing for this campaign is now — 20% of Congress members include newly elected legislators who are focused on reining in government spending. “They need to hear about the ways in which pharmacy services can help increase medication adherence, thus reducing preventable and more costly healthcare expenditures,” Anderson wrote.
The ads advocate for congressional support of S.274, the NACDS-backed Medication Therapy Management Empowerment Act. The print ad is pictured here.
“This is what a trade association sounds like when it truly shouts from the rooftops, and these powerful sounds are absolutely necessary for success,” Anderson concluded.
Watson promotes two SVPs
MORRISTOWN, N.J. — Generic drug maker Watson Pharmaceuticals has promoted two executives to EVP, the company said Wednesday.
The company gave the promotions to SVP, general counsel and secretary David Buchen and SVP and CFO R. Todd Joyce. Both will continue to report to CEO Paul Bisaro.
“These promotions not only recognize the substantial individual contributions David and Todd have made to Watson’s ongoing success, but also the significant achievements made by both in building the teams that support our company’s global growth,” Bisaro said.
Buchen began working for Watson in 1998, while Joyce began with the company in 1997.
Merck seeks FDA approval for Saflutan
WHITEHOUSE STATION, N.J. — The Food and Drug Administration has accepted an approval application from Merck for a drug to treat eye diseases, Merck said Wednesday.
Merck is seeking approval for Saflutan (tafluprost) ophthalmic solution, an investigational drug for relieving eye pressure in patients with glaucoma and ocular hypertension.
“Merck has been providing new therapies to help treat eye diseases for more than 50 years,” said Joseph Markoff, Merck global director for scientific affairs in ophthalmology. “The acceptance of the [new drug approval] submission for tafluprost is an important milestone in our effort to bring forward an additional therapeutic option for patients with primary, open-angle glaucoma or ocular hypertension.”